BeiGene Ltd (SHSE:688235)
Â¥ 133.37 1.74 (1.32%) Market Cap: 134.50 Bil Enterprise Value: 122.01 Bil PE Ratio: 0 PB Ratio: 5.37 GF Score: 55/100

Beigene Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 14, 2021 / 10:20PM GMT
Ling Wang
JPMorgan Chase & Co, Research Division - Executive Director & Senior Greater China Healthcare Analyst

Good afternoon, and good morning, everyone, and welcome to the JPMorgan Healthcare Conference. My name is Ling Wang. I'm a senior China healthcare analyst here at JPMorgan. So our next presenting company is BeiGene, a leading biotech companies in China that is dual-listed on NASDAQ and Hong Kong Stock Exchange. So presenting for the company is the CEO and Chairman, Mr. John Oyler.

Before I turn it over to John, I just wanted to remind everyone, there will be a Q&A session right after his presentation at this same Zoom meeting. (Operator Instructions)

So with that, John, thank you so much for being with us today. Let me turn this over to you.

John V. Oyler
BeiGene, Ltd. - Co-Founder, Chairman & CEO

Thank you, Ling. Hello, everyone, and welcome to BeiGene's presentation. I'm John Oyler, the CEO and Co-Founder. Thank you to JPMorgan for having us here today. We've heard from many investors that our story is complex,

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot